A rough guide to…advisory boards

PMLive | March 23, 2016

Our intrepid writers take us on a journey through advisory boards and show that pre-trip planning is the pathway to perfection

Read more ›

Nine Key Elements to Ensure Advisory Board Success

PM360 | June 17, 2014

The relationship between pharmaceutical companies and medical stakeholders will need to evolve thanks to the greater public scrutiny these relationships will now receive under various regulatory changes including the Sunshine Act.

Read more >

Getting the Right Relationship Between Doctors and Drug Companies

The Atlantic | May 7, 2013

There is a way to cultivate, not demonize, collaboration between physicians and pharma.

Read more >

Pharma Medical Affairs: 2020 and Beyond

McKinsey & Company | 2014

Pharma’s Medical Affairs faces growing internal and external challenges as
well as new opportunities

Read more >

Patients, Physicians, and Payers…How Can Pharma Do It All?

PharmaExec.com | March 18, 2015

The word ‘centric’ by definition means one, as in focused on a single entity. Yet, in today’s life sciences industry, companies are customer-centric and patient-centric and physician-centric – combined, it’s counterintuitive…if not overwhelming.

Read more >

Pharmaceutical companies should focus on medication adherence to improve revenue

Healthcare Finance Network | June 14, 2018

A more concerted effort by pharmaceutical companies to drive medication adherence could help them increase their sales growth and margin profile.

Read more >

Medical Affairs: the navigator of pharma’s new world order

PharmaTimes Online | July 2018

The most important role in the emerging future of the pharmaceutical industry is medical affairs – a responsibility long viewed as a support function.

Read more ›

Doctors and pharmaceutical companies work together to improve patient care-not pad pockets | Opinion

Penn Live | August 22, 2018

In recent years there has been a push towards more transparency regarding the financial relationship between physicians and pharmaceutical companies.

Read more >

An Unwarranted Attack on Rare Disease Research

Forbes | August 28, 2018

Is the FDA really “less fussy about the kind of data that it requires for approval of a new drug for a rare disease“?

Read more >

Three Key Components of Multichannel Marketing to Healthcare Providers

Forbes | January 11, 2019

Impactful multichannel marketing (MCM) cam­paigns that take HCPs on relevant, personalized journeys are the cornerstone of this objective.

Read more >